Actavis Reaches Tentative Deal To Exit Testosterone MDL

Law360 (June 29, 2018, 6:12 PM EDT) -- Actavis Inc. is on its way to settling claims it failed to warn men about risks associated with its drug Androderm as part of multidistrict litigation over testosterone replacement therapy products, according to an order filed Friday.

In the order staying cases in the MDL against Actavis and several related entities, U.S. District Judge Matthew Kennelly said attorneys for both sides told him they have reached a memorandum of understanding on a potential global settlement.

Actavis is only the latest pharmaceutical company to head for the exit in the MDL in recent months. Auxilium Pharmaceuticals LLC, Eli Lilly & Co., Endo...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!